| Status: Recommended | ||
Rivaroxaban (Xarelto®) granules for oral suspension and film-coated tablets are recommended as an option for use within NHS Wales, for the treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in term neonates, infants and toddlers, children, and adolescents aged less than 18 years after at least 5 days of initial parenteral anticoagulation treatment. |
||
|
||
Medicine details |
||
| Medicine name | rivaroxaban (Xarelto®) | |
| Formulation | 1 mg/1ml granules for oral suspension; 15 mg and 20 mg film-coated tablet | |
| Reference number | 3875 | |
| Indication | Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in term neonates, infants and toddlers, children, and adolescents aged less than 18 years after at least 5 days of initial parenteral anticoagulation treatment |
|
| Company | Bayer Healthcare Pharmaceuticals | |
| BNF chapter | Cardiovascular system | |
| Submission type | Licence extension for paediatric use | |
| Status | Recommended | |
| Advice number | 1721 | |
| AWMSG meeting date | 08/12/2021 | |
| Date of issue | 10/12/2021 | |
| NICE guidance | See also NICE TA287: Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (in adults) and TA261: Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (in adults) |
|